Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany

Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany

<p>Abstract</p> <p>Objective</p> <p>Avoiding abacavir in HIV-infected patients tested positive for HLA-B*5701 reduces the risk of abacavir hypersensitivity reaction (ABC-HSR). Our aim was to assess the costs of clinically suspected HSR and to estimate potential cost sav...

Full description

Bibliographic Details
Main Authors: Wolf E, Blankenburg M, Bogner JR, Becker W, Gorriahn D, Mueller MC, Jaeger H, Welte R, Baudewig M, Walli R, Stoll M
Format: Article
Language:English
Published: BMC 2010-04-01
Series:European Journal of Medical Research
Subjects:
HLA-B*5701
pharmacogenomics
abacavir
Online Access:http://www.eurjmedres.com/content/15/4/145

Similar Items

Similar Items